GeneCentric Therapeutics, Inc.

Biotechnology ResearchNorth Carolina, United States11-50 Employees

GeneCentric is a precision oncology company transforming cancer diagnostics and genomic profiling through the power of gene expression. With a foundation built on over a decade of research into gene expression, including the PurIST® test (commercially available through Tempus), GeneCentric has pioneered ExpressCT™, a proprietary technology that enables gene expression inference directly from circulating tumor DNA (ctDNA). This innovation is embodied in the GenomicsNext™ platform, a multimodal liquid biopsy solution that simultaneously detects DNA alterations and inferred gene expression from a single blood sample.
Unlike traditional liquid biopsy alteration testing that focus solely on static DNA mutations, GenomicsNext™ unlocks dynamic, functional insights into the tumor’s “on state,” enhancing biomarker discovery, therapy selection, and clinical trial enrichment. 

GeneCentric partners with biopharma, diagnostic developers, and researchers to enable expression-driven companion diagnostics, particularly for emerging therapies like antibody-drug conjugates (ADCs), and to develop novel blood-based biomarkers that address current gaps in cancer care.

Through its cutting-edge technology and deep expertise, GeneCentric is expanding the boundaries of what ctDNA can reveal and advancing the next generation of precision medicine.

Sign up for free to view info

Email Format Employee directory